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Left main coronary artery disease (LMCAD) is identified in about 5% of 
patients undergoing coronary arteriography for the assessment of 
obstructive coronary artery disease (CAD) and is associated with increased 
morbidity and mortality.1 For decades, coronary artery bypass grafting 
(CABG) has been the gold standard treatment for LMCAD. However, with 
continuing advances in interventional cardiology, percutaneous coronary 
intervention (PCI) has become a safe and effective management option in 
selected patients with LMCAD.2
The XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of 
Left Main Revascularization (EXCEL) trial assessed the safety and efficacy 
of CABG versus PCI for the management of LMCAD. The authors reported 
their 3-year follow-up data in December 2016 and 5-year follow-up data 
in September 2019.3,4 
In this contemporary, non-inferiority trial, 1,905 patients with low or 
intermediate anatomical complexity LMCAD were randomly assigned to 
undergo either PCI with fluoropolymer-based cobalt-chromium 
everolimus-eluting stents (PCI group, n=948) or CABG (CABG group, 
n=957). Results at 30-day, 3- and 5-year follow-up are shown in Table 1. 
The authors concluded that treatment with PCI and CABG did not differ 
significantly regarding the composite outcome of death, stroke or MI in 
patients with LMCAD of low or intermediate anatomical complexity.
Although the EXCEL trial has many strengths including its recruitment and 
successful follow-up of a large number of patients, the interpretation of its 
findings has generated controversy and the lead surgical investigator 
withdrew his name from its final publication. Moreover, in December 2019, 
the European Association for Cardio-thoracic Surgery council withdrew its 
support for the treatment recommendations on LMCAD published in the 
2018 European Society of Cardiology/European Association for Cardio-
thoracic Surgery myocardial revascularisation guidelines that were largely 
based on the EXCEL trial findings.5 
A number of issues in the trial have been extremely controversial and 
debated by the scientific community worldwide. Two main issues have 
captured the attention of clinicians, researchers and patients alike:
• The reporting of the overall results as ‘neutral’ at 5-years follow-up 
with similar outcomes for CABG and PCI treatments.
• Discrepancies that emerged after the publication of the study 
regarding the definition of periprocedural MI used in the trial. 
‘Neutral’ Overall Results
The authors reported that in patients with LMCAD and a low and 
intermediate SYNTAX score, the study’s composite primary endpoint – 
death, stroke or MI – at 5 years was 22% in the PCI group and 19.2% in the 
CABG group (p=0.13) and concluded that there were no significant 
differences between revascularisation with PCI or CABG. Moreover, all-
cause mortality was reported as being essentially equal between the PCI 
and CABG groups at 1 and 2 years but it began to diverge in a sustained 
fashion such that endpoint rates became 13.0% versus 9.9% (OR 1.38; 
95% CI [1.03– 1.85]) by 5 years. The mortality rate at 5 years was 38% 
higher in the PCI arm compared to the CABG arm. 
To provide additional insights into the interpretation of data reported by 
EXCEL, Bayesian methods were proposed, which give probability 
estimates of clinical interest and allow the consideration of pre-existing 
evidence and how it can influence test results and aid medical decision-
making.6 These methods have been recommended to assist in the 
interpretation of clinical trials for more than 20 years.7 Reanalysis of the 
EXCEL trial data with the use of Bayesian methods resulted in the opposite 
conclusions to what was initially reported by the EXCEL investigators: the 
mean difference regarding incidence of the primary composite outcome 
was 3% lower in the CABG group compared to the PCI, whereas mortality 
was 1% lower with CABG than with PCI at 5 years. Similar results were 
reported in a systematic review of all previous CABG versus PCI studies. 
This analysis suggests that long-term results with the use of PCI are 
inferior to CABG in patients with LMCAD.8 
Discrepancies in the Different 
Definition of MI in the EXCEL Trial
In the EXCEL protocol, the universal definition of MI from the joint 
European Society of Cardiology/American College of Cardiology/American 
Heart Association/World Heart Federation Task Force for the Redefinition 
of MI was a pre-specified secondary endpoint. However, the EXCEL 
investigators used the Society for Cardiovascular Angiography and 
Interventions (SCAI) definition of MI when the results were reported. This 
is problematic, as the universal definition was a pre-specified secondary 
endpoint in the original EXCEL protocol and this definition was not used in 
the 3-year or 5-year publications. 
Post-revascularisation myonecrosis was assessed after PCI and CABG by 
serial measurements of creatine kinase-MB (CK-MB) and defined using an 
identical threshold for PCI and CABG (CK-MB elevation >10 × the upper 
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reference limit (URL) within 72 hours post-procedure, or >5× URL with new 
Q waves, angiographic vessel occlusion or loss of myocardium on 
imaging). Troponin assessments were optional and, according to the 
authors, were collected in a minority of patients, which seriously 
compromises the diagnosis of procedural MI using alternative definitions. 
In a letter to the editor published in the New England Journal of Medicine 
in July 2020, the authors provided evidence on the cumulative incidence 
of MI at the 5-year follow-up using the third universal definition of MI and 
a large discrepancy has become apparent in the number of CABG-related 
procedural MIs when data using these two different definitions are 
compared.9,10 Unfortunately, the letter did not include a calculation of the 
primary composite outcome using the universal definition of MI.
Conclusion
The evidence indicates that the jury is still out as to whether CABG or PCI 
is a better treatment option for patients with LMCAD and the issue 
continues to be debated. A review process initiated by the NEJM is under 
way and it is hoped that its conclusions will help gain insight into the true 
findings of the EXCEL trial. 
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Table 1: EXCEL Trial Outcomes at 30 Days, 3 Years and 5 Years














Death, stroke or MI 4.9% 7.9% 0.61 [0.42–0.88] 0.008 15.4% 14.7% 1.00 [0.79–1.26] 0.98 22.0% 19.2% 1.19 [0.95–1.50]
Death 1.0% 1.1% 0.90 [0.37–2.22] 0.82 8.2% 5.9% 1.34 [0.94–1.91] 0.11 13.0% 9.9% 1.38 [1.03–1.85]
Stroke 0.6% 1.3% 0.50 [0.19–1.33] 0.15 2.3% 2.9% 0.77 [0.43–1.37] 0.37 2.9% 3.7% 0.78 [0.46–1.31]
MI 3.9% 6.2% 0.63 [0.42–0.95] 0.02 8.0% 8.3% 0.93 [0.67–1.28] 0.64 10.6% 9.1% 1.14 [0.84–1.55]
Values are presented as event rate (%). CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention
